Tyme Technologies Inc (NASDAQ:TYME) Major Shareholder Michael Demurjian Sells 20,000 Shares

Tyme Technologies Inc (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $1.00, for a total transaction of $20,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Michael Demurjian also recently made the following trade(s):

  • On Monday, August 5th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.12, for a total transaction of $22,400.00.
  • On Monday, July 29th, Michael Demurjian sold 50,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.11, for a total transaction of $55,500.00.
  • On Monday, July 22nd, Michael Demurjian sold 50,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.18, for a total transaction of $59,000.00.

TYME stock traded up $0.04 during mid-day trading on Tuesday, hitting $1.01. 585,900 shares of the company were exchanged, compared to its average volume of 746,537. The firm’s fifty day simple moving average is $1.18. Tyme Technologies Inc has a 12-month low of $0.92 and a 12-month high of $4.64. The stock has a market capitalization of $109.71 million, a price-to-earnings ratio of -3.16 and a beta of 0.40.



Tyme Technologies (NASDAQ:TYME) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. Equities research analysts expect that Tyme Technologies Inc will post -0.34 earnings per share for the current fiscal year.

TYME has been the subject of a number of recent research reports. Zacks Investment Research cut shares of Tyme Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th. HC Wainwright assumed coverage on shares of Tyme Technologies in a research report on Monday. They set a “buy” rating for the company.

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its position in shares of Tyme Technologies by 151.1% during the fourth quarter. BlackRock Inc. now owns 5,187,396 shares of the company’s stock valued at $19,140,000 after acquiring an additional 3,121,655 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Tyme Technologies by 242.9% during the fourth quarter. Bank of New York Mellon Corp now owns 289,819 shares of the company’s stock valued at $1,070,000 after acquiring an additional 205,300 shares in the last quarter. Northern Trust Corp increased its position in shares of Tyme Technologies by 26.5% during the fourth quarter. Northern Trust Corp now owns 485,786 shares of the company’s stock valued at $1,793,000 after acquiring an additional 101,734 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Tyme Technologies by 263.0% during the fourth quarter. Geode Capital Management LLC now owns 689,612 shares of the company’s stock valued at $2,544,000 after acquiring an additional 499,627 shares in the last quarter. Finally, Bank of America Corp DE increased its position in shares of Tyme Technologies by 1,066.6% during the fourth quarter. Bank of America Corp DE now owns 42,849 shares of the company’s stock valued at $158,000 after acquiring an additional 39,176 shares in the last quarter. 19.58% of the stock is owned by institutional investors and hedge funds.

About Tyme Technologies

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Featured Story: Dead Cat Bounce

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.